eMedicine Specialties > Neurology > Neurological Infections

Herpes Simplex Encephalitis

Author: Wayne E Anderson, DO, Assistant Professor of Internal Medicine/Neurology, Western University of Health Sciences; Assistant Professor of Family Medicine, Touro University College of Osteopathic Medicine; Consulting Staff in Pain Management, Department of Neurology, California Pacific Medical Center
Contributor Information and Disclosures

Updated: Sep 2, 2009

Introduction

Background

The human herpesvirus (HHV) family includes 2 clinically important strains, also known as herpes simplex virus (HSV). Human herpesvirus 1 (HHV-1), also called herpes simplex virus type 1 (HSV-1), causes oral lesions (so-called fever blisters); these are common and may respond to antiviral medications, although they spontaneously remit in most cases. Human herpesvirus 2 (HHV-2), also known as herpes simplex virus type 2 (HSV-2), causes genital lesions. It was previously thought to appear within 1-2 weeks of primary infection, then to recur with lessening severity. That lesions may appear clinically at any interval after primary infection is now known. HSV-2 may be treated with antiviral medications.

Patients with HSV may require long-term antiviral treatment if they have recurrent lesions or involvement of other organ systems (eg, herpes simplex keratitis). HSV remains dormant in the nervous system; rarely, it presents as encephalitis, possibly by direct transmission through peripheral nerves to the CNS. This encephalitis is a neurologic emergency and the most important neurologic sequela of HSV.

Pathophysiology

Besides causing local outbreaks, HSV-1 and HSV-2 are associated with encephalitis. HSV-1 is the more common cause of adult encephalitis. HSV-2 is the more common cause of newborn encephalitis, which is associated with maternal genital infections. Pathophysiology of this encephalitis is poorly understood in humans. Animal models suggest that the virus enters the CNS via peripheral nerves. Virus-induced apoptosis may play a role in the molecular pathogenesis of herpes simplex encephalitis (HSE). HSV is an enveloped, double-stranded DNA virus. It is part of the herpes family, which also includes varicella-zoster virus (VZV, or HHV-3) and cytomegalovirus (CMV, or HHV-5).

The encephalitis affects the temporal lobes of the brain in most cases. Wasay et al report temporal lobe involvement in 60% of patients.1 Fifty-five percent of patients demonstrated temporal and extratemporal pathology, and 15% of patients demonstrated extratemporal pathology exclusively.

Frequency

United States

HSE is the most common nonepidemic encephalitis. Incidence is 2 cases per million population per year. HSE may occur year-round. HSV-1 is ubiquitous and HSV-2 is also common.

International

International incidence is similar to that in the United States.

Mortality/Morbidity

HSV-1 and HSV-2 infections often recur. HSE rarely occurs. Untreated HSE is progressive and often fatal in 7-14 days. However, significant morbidity exists among those treated. A landmark study by Whitley et al in 1977 revealed a 70% mortality rate in untreated patients and severe neurologic deficits in most of the survivors.2 The following demonstrate the variety of complications.

  • Elbers and colleagues followed properly treated children for 12 years after the HSE. They found seizures in 44% of the children and developmental delay in 25% of the children. They concluded that HSE continues to be associated with poor long-term neurologic outcomes despite appropriate therapy.3
  • Shelley and colleagues reported a case of intracerebral hematoma occurring in a patient successfully treated with a full course of acyclovir after apparent eradication of the virus. The hematoma occurred in the region of the encephalitis.4
  • Marschitz and colleagues reported a case of chorea after HSE.5

Sex

  • Herpes affects both sexes equally.
  • Genital herpes may be more apparent in the male because of anatomy.

Age

One third of HSE cases occur in children.

Clinical

History

  • In HSE, patients may have a prodrome of malaise, fever, headache, and nausea.
  • This is followed by acute or subacute onset of an encephalopathy whose symptoms include lethargy, confusion, and delirium.
  • Headaches, seizures, aphasia, and other focal deficits also may occur.

Physical

  • On neurologic examination, global and focal neurologic findings include encephalopathy, delirium, aphasia, cranial nerve deficits, and hemiparesis.
  • Meningeal signs may be present.
  • Unusual presentations occur. Both HSV-1 and HSV-2 may produce a more subacute encephalitis, apparent psychiatric syndromes, and benign recurrent meningitis. Less commonly, HSV-1 may produce a brain stem encephalitis and HSV-2, a myelitis.
    • Ku et al discussed the unique presentation of HSE in a bilingual patient. He developed global aphasia for 1 language (his most recently learned language) but retained most of his birth language ability.6
    • McGrath et al reported on 4 patients with confirmed HSE, each with an anterior opercular syndrome. The syndrome (ie, paralysis of the masticatory, facial, pharyngeal, and lingual muscles) occurred as the primary manifestation of HSE in 2 patients and as part of the encephalitis picture in the other 2 patients. The authors suggested that unique presentations, such as the anterior opercular syndrome, should alert the clinician to the possibility of HSE.7
    • Mondal et al report basal ganglia involvement in a child with HSE, demonstrating extrapyramidal symptoms.8
    • Li and Sax report HSE-associated cerebral hemorrhage in an HIV-positive person.9

Causes

  • In adults, the host immune response, combined with viral factors, determines invasiveness and virulence.
    • Mitchell et al showed that invasiveness of HSV-1 glycoprotein variants is controlled by host response.10
    • Geiger et al used interferon-gamma–knockout mice to show how interferon-gamma protected against HSV-1–mediated neuronal death.11
    • These data suggested that the presentation and severity of encephalitis vary.
  • Evidence from a European study suggested that socioeconomic status and geography might affect levels of virus seropositivity. However, clinical correlation is difficult because HSE can occur at any time, regardless of the patient's socioeconomic status, age, race, or sex.
  • In children, encephalitis often results from primary infection with HSV. Approximately 80% of children with HSE do not have a history of labial herpes.
  • In newborns, a preexisting but recurrent maternal genital herpes infection results in 8% risk of symptomatic infection, usually transmitted at the second stage of labor via direct contact. Should the mother acquire genital herpes during pregnancy, the risk increases to 40%.
  • Cathomas et al report a case of HSE as a complication of chemotherapy for breast cancer.12

More on Herpes Simplex Encephalitis

Overview: Herpes Simplex Encephalitis
Differential Diagnoses & Workup: Herpes Simplex Encephalitis
Treatment & Medication: Herpes Simplex Encephalitis
Follow-up: Herpes Simplex Encephalitis
References

References

  1. Wasay M, Mekan SF, Khelaeni B, et al. Extra temporal involvement in herpes simplex encephalitis. Eur J Neurol. Jun 2005;12(6):475-9. [Medline].

  2. Whitley RJ, Soong SJ, Dolin R, et al. Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. N Engl J Med. Aug 11 1977;297(6):289-94. [Medline].

  3. Elbers JM, Bitnun A, Richardson SE. A 12-year prospective study of childhood herpes simplex encephalitis: is there a broader spectrum of disease?. Pediatrics. Feb 2007;119(2):e399-407. [Medline].

  4. Shelley BP, Raniga SB, Al-Khabouri J. An unusual late complication of intracerebral haematoma in herpes encephalitis after successful acyclovir treatment. J Neurol Sci. Jan 31 2007;252(2):177-80. [Medline].

  5. Marschitz I, Rodl S, Gruber-Sedlmayr U. Severe chorea with positive anti-basal ganglia antibodies after herpesencephalitis. J Neurol Neurosurg Psychiatry. Jan 2007;78(1):105-7. [Medline].

  6. Ku A, Lachmann EA, Nagler W. Selective language aphasia from herpes simplex encephalitis. Pediatr Neurol. Sep 1996;15(2):169-71. [Medline].

  7. McGrath NM, Anderson NE, Hope JK, et al. Anterior opercular syndrome, caused by herpes simplex encephalitis. Neurology. Aug 1997;49(2):494-7. [Medline].

  8. Mondal G, Kumar R, Ghosh JK, Basu K, Chatterjee S. Basal ganglia involvement in a child with herpes simplex encephalitis. Indian J Pediatr. May 27 2009;[Medline].

  9. Li JZ, Sax PE. HSV-1 encephalitis complicated by cerebral hemorrhage in an HIV-positive person. AIDS Read. Apr 2009;19(4):153-5. [Medline].

  10. Mitchell BM, Stevens JG. Neuroinvasive properties of herpes simplex virus type 1 glycoprotein variants are controlled by the immune response. J Immunol. Jan 1 1996;156(1):246-55. [Medline].

  11. Geiger KD, Nash TC, Sawyer S, et al. Interferon-gamma protects against herpes simplex virus type 1-mediated neuronal death. Virology. Nov 24 1997;238(2):189-97. [Medline].

  12. Cathomas R, Pelosi E, Smart J. Herpes simplex encephalitis as a complication of adjuvant chemotherapy treatment for breast cancer. Clin Oncol (R Coll Radiol). Jun 2005;17(4):292-3. [Medline].

  13. Schloss L, Falk KI, Skoog E, Brytting M, Linde A, Aurelius E. Monitoring of herpes simplex virus DNA types 1 and 2 viral load in cerebrospinal fluid by real-time PCR in patients with herpes simplex encephalitis. J Med Virol. Jun 23 2009;81(8):1432-1437. [Medline].

  14. Beneto A, Gomez E, Rubio P, et al. [Periodical EEG pattern modifications in herpetic encephalitis treated with acyclovir]. Rev Neurol. Jul 1996;24(131):829-32. [Medline].

  15. [Best Evidence] Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev. Jan 21 2009;CD006706. [Medline].

  16. Utley TF, Ogden JA, Gibb A, et al. The long-term neuropsychological outcome of herpes simplex encephalitis in a series of unselected survivors. Neuropsychiatry Neuropsychol Behav Neurol. Jul 1997;10(3):180-9. [Medline].

  17. Athmanathan S, Vydehi BV. Neuronal apoptosis in herpes simplex virus-1 encephalitis (HSE). Medical Microbiology. 2001;19:127-131.

  18. Baxter P, Forsyth R, Eyre J. Relapse and movement disorder after herpes simplex encephalitis. J Child Neurol. Jun 1997;12(4):283. [Medline].

  19. Brown ZA, Vontver LA, Benedetti J, et al. Effects on infants of a first episode of genital herpes during pregnancy. N Engl J Med. Nov 12 1987;317(20):1246-51. [Medline].

  20. Cinque P, Cleator GM, Weber T, et al. The role of laboratory investigation in the diagnosis and management of patients with suspected herpes simplex encephalitis: a consensus report. The EU Concerted Action on Virus Meningitis and Encephalitis. J Neurol Neurosurg Psychiatry. Oct 1996;61(4):339-45. [Medline].

  21. Hasegawa T, Kanno S, Kato M, et al. Neuro-Behçet's disease presenting initially as mesiotemporal lesions mimicking herpes simplex encephalitis. Eur J Neurol. Aug 2005;12(8):661-2. [Medline].

  22. Jereb M, Lainscak M, Marin J, Popovic M. Herpes simplex virus infection limited to the brainstem. Wien Klin Wochenschr. Jul 2005;117(13-14):495-9. [Medline].

  23. Preiser W, Weber B, Klos G, et al. Unusual course of herpes simplex virus encephalitis after acyclovir therapy. Infection. Sep-Oct 1996;24(5):384-9. [Medline].

  24. Shian WJ, Chi CS. Magnetic resonance imaging of herpes simplex encephalitis. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. Jan-Feb 1996;37(1):22-6. [Medline].

  25. Whitley RJ. Viral encephalitis. N Engl J Med. Jul 26 1990;323(4):242-50. [Medline].

  26. Whitley RJ, Soong SJ, Linneman C Jr, et al. Herpes simplex encephalitis. Clinical Assessment. JAMA. Jan 15 1982;247(3):317-20. [Medline].

Further Reading

Keywords

herpes, genital herpes, herpes encephalitis, encephalitis, HSE, HSV-1, HSV-2, cold sores, fever blisters, herpes simplex virus, human herpesvirus, HHV, HHV-1, herpes simplex virus type 1, herpes simplex virus type 2, herpes simplex encephalitis

Contributor Information and Disclosures

Author

Wayne E Anderson, DO, Assistant Professor of Internal Medicine/Neurology, Western University of Health Sciences; Assistant Professor of Family Medicine, Touro University College of Osteopathic Medicine; Consulting Staff in Pain Management, Department of Neurology, California Pacific Medical Center
Wayne E Anderson, DO is a member of the following medical societies: American Academy of Neurology, American Medical Association, American Society of Law Medicine and Ethics, California Medical Association, and San Francisco Medical Society
Disclosure: Cephalon Honoraria Speaking and teaching; Pfizer Honoraria Speaking and teaching; King Honoraria Consulting

Medical Editor

Ramon Diaz-Arrastia, MD, PhD, Assistant Professor, Department of Neurology, Comprehensive Epilepsy Center, University of Texas Southwestern
Ramon Diaz-Arrastia, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, New York Academy of Sciences, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital
Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association
Disclosure: Nothing to disclose.

CME Editor

Matthew J Baker, MD, Consulting Staff, Collier Neurologic Specialists, Naples Community Hospital
Matthew J Baker, MD is a member of the following medical societies: American Academy of Neurology
Disclosure: Nothing to disclose.

Chief Editor

Nicholas Y Lorenzo, MD, Chief Editor, eMedicine Neurology; Consulting Staff, Neurology Specialists and Consultants
Nicholas Y Lorenzo, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Neurology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.